CORK, Ireland, Nov. 05, 2026 (GLOBE NEWSWIRE) — ArrayPatch Ltd (\u201cArrayPatch\u201d), a biotech company developing innovative microneedle-based therapeutics, today announced the successful completion of the second close of its seed financing round, securing an additional \u20ac1.6 million, bringing the total raised to \u20ac3.2 million. The latest investment comes from impact-focused venture capital firm WakeUp Capital along with funds raised via Spark Venture Funding and Dr. Mark Ledwidge plus existing lead investor Lakeside Capital and DeepIE Ventures.<\/p>\n
The proceeds from the seed financing will be used to accelerate the development of programs leveraging its proprietary DerMap\u2122\u00a0dissolving microneedle patch platform towards first-in-human studies, with an initial focus on GLP-DerMap\u2122\u00a0for the treatment of obesity and diabetes, and VIS-DerMap\u2122\u00a0for the treatment of basal cell carcinoma. DerMap\u2122\u00a0is the only microneedle patch delivery technology whereby the microneedles are made entirely from the medicine being delivered, thus requiring no polymer, allowing significantly higher drug loading capacity. The platform can be used to deliver both small molecules and peptides.<\/p>\n
\u201cThe successful completion of our \u20ac3.2 million seed round is an important milestone for ArrayPatch and provides the resources to accelerate the development of our pipeline,\u201d said Dr. Waleed Faisal, Founder and CEO of ArrayPatch. \u201cOur primary focus is now GLP-DerMap\u2122, where we believe our technology has the potential to offer a new, patient-friendly approach to the delivery of GLP-1 medicines. We are also continuing to advance our programmes in skin cancer and nail fungal infection.\u201d<\/p>\n
\u201cWe are delighted to co-lead this round as ArrayPatch is advancing a novel technology designed to address numerous patient and environmental challenges associated with medicines administered by traditional injections, setting the company on track to make a significant global human and environmental impact.\u201d said Andrew Parish, Partner at WakeUp Capital.<\/p>\n
Additional investors in the \u20ac3.2 million seed round included Enterprise Ireland, The Boole Investment Syndicate and a number of private investors. Andrew Parish, Partner at WakeUp Capital, will join the ArrayPatch Board of Directors, alongside recently appointed Chair, Dr. Neil Thomas.<\/p>\n
About ArrayPatch Ltd<\/strong><\/p>\n ArrayPatch is a biotech company based in Cork, Ireland, developing next-generation microneedle-based therapeutics. Its DerMap\u2122 platform harnesses polymer-free dissolving microneedles to deliver therapeutic agents directly in a painless and efficient manner. The company\u2019s lead program, GLP-DerMap\u2122, is designed to address the challenges associated with current GLP-1 agonist injections by delivering the medicine in a pain-free patch and is currently in pre-clinical development. Additional applications under development are VIS-DerMap\u2122\u00a0for the treatment of basal cell carcinoma and ITZ-DerMap\u2122\u00a0for the treatment of onychomycosis (nail fungus). ArrayPatch was spun out from University College Cork and has secured significant non-dilutive funding and industry recognition to support its development strategy. For more information, please visit www.array-patch.com<\/a><\/p>\n